| Literature DB >> 22615631 |
M R Khoshayand1, H Abdollahi, A Ghaffari, M Shariatpanahi, H Farzanegan.
Abstract
BACKGROUND AND THE PURPOSE OF THE STUDY: The linear multivariate calibration models such as principal components regression (PCR) and partial least squares regressions (PLS1 and PLS2) due to the mathematical simplicity and physical or chemical interpretability are sufficient and generally preferred method for analysis of multicomponent drugs. In this study, simultaneous determination of paracetamol, phenylephrine and chlorpheniramine in pharmaceuticals using chemometric methods and UV spectrophotometry is reported as a simple alternative technique.Entities:
Keywords: Partial least squares regressions (PLS1, PLS2); Principal components regression (PCR)
Year: 2010 PMID: 22615631 PMCID: PMC3304346
Source DB: PubMed Journal: Daru ISSN: 1560-8115 Impact factor: 3.117
Figure 1Absorbance spectra of: (I) 10 µg ml-1 Paracetamol; (II)10 µg ml-1 Phenylephrine; (III) 10 µg ml-1 Chlorpheniramine in methanol: 0.1 M HCl (3:1).
Composition of the calibration set for applying PCR, PLS1 and PLS2 methods.
| Number of calibration sample | PCT (µgml-1) | PHEN (µgml-1) | CHL (µgml-1) |
|---|---|---|---|
| 1 | 20.0 | 20.0 | 6.0 |
| 2 | 15.0 | 12.0 | 16.0 |
| 3 | 18.0 | 1.0 | 1.0 |
| 4 | 19.0 | 17.0 | 1.0 |
| 5 | 18.0 | 12.0 | 15.0 |
| 6 | 10.0 | 2.0 | 14.0 |
| 7 | 19.0 | 12.0 | 10.0 |
| 8 | 7.0 | 8.0 | 9.0 |
| 9 | 2.0 | 17.0 | 6.0 |
| 10 | 14.0 | 2.0 | 17.0 |
| 11 | 12.0 | 1.0 | 10.0 |
| 12 | 3.0 | 7.0 | 2.0 |
| 13 | 17.0 | 13.0 | 2.0 |
| 14 | 4.0 | 17.0 | 18.0 |
| 15 | 1.0 | 12.0 | 18.0 |
| 16 | 19.0 | 14.0 | 15.0 |
| 17 | 4.0 | 14.0 | 4.0 |
| 18 | 14.0 | 15.0 | 2.0 |
| 19 | 15.0 | 11.0 | 15.0 |
| 20 | 10.0 | 3.0 | 11.0 |
Figure 2Plot of PRESS against the number of factors for PCT, PHEN and CHL.
Composition of synthetic samples, their predictions by PCR model and statistical parameters for the system.
| Synthetic (µgml-1) | Prediction(µgml-1) | Recovery (%) | ||||||
|---|---|---|---|---|---|---|---|---|
| PCT | PHEN | CHL | PCT | PHEN | CHL | PCT | PHEN | CHL |
| 18.0 | 10.0 | 16.0 | 17.8 | 10.3 | 14.7 | 98.9 | 103.0 | 91.9 |
| 17.0 | 1.0 | 11.0 | 17.8 | 0.98 | 11.01 | 104.7 | 98.0 | 100.1 |
| 9.0 | 20.0 | 16.0 | 8.3 | 19.7 | 15.8 | 92.2 | 98.5 | 98.8 |
| 9.0 | 13.0 | 6.0 | 8.8 | 13.1 | 5.2 | 97.8 | 100.8 | 86.7 |
| 16.0 | 4.0 | 19.0 | 15.8 | 4.1 | 17.8 | 98.8 | 102.5 | 93.7 |
| 2.0 | 10.0 | 11.0 | 2.3 | 9.7 | 10.7 | 115.0 | 97.0 | 97.3 |
| 10.0 | 13.0 | 20.0 | 8.9 | 13.3 | 19.2 | 89.0 | 102.3 | 96.0 |
| 4.0 | 1.0 | 15.0 | 4.1 | 1.1 | 15.1 | 102.5 | 101.0 | 100.7 |
| 5.0 | 7.0 | 11.0 | 4.8 | 6.3 | 11.5 | 96.0 | 90.0 | 104.5 |
| 19.0 | 13.0 | 4.0 | 18.8 | 13.8 | 3.8 | 98.9 | 106.2 | 95.0 |
| Mean recovery | 99.4 | 99.9 | 96.5 | |||||
| R.S.E. (%) single | 4.14 | 3.58 | 5.03 | |||||
| R.S.E. (%) total | 4.41 | |||||||
Composition of synthetic samples, their predictions by PLS2 model and statistical parameters for the system.
| Synthetic (µgml-1) | Prediction (µgml-1) | Recovery (%) | ||||||
|---|---|---|---|---|---|---|---|---|
| PCT | PHEN | CHL | PCT | PHEN | CHL | PCT | PHEN | CHL |
| 18.0 | 10.0 | 16.0 | 18.2 | 9.9 | 15.5 | 101.1 | 99.0 | 96.9 |
| 17.0 | 1.0 | 11.0 | 17.5 | 1.07 | 11.3 | 102.9 | 107.0 | 102.7 |
| 9.0 | 20.0 | 16.0 | 9.1 | 20.1 | 16.1 | 101.1 | 100.5 | 100.6 |
| 9.0 | 13.0 | 6.0 | 8.3 | 12.8 | 6.6 | 92.2 | 98.5 | 110.0 |
| 16.0 | 4.0 | 19.0 | 16.3 | 3.8 | 18.3 | 101.9 | 95.0 | 96.3 |
| 2.0 | 10.0 | 11.0 | 1.9 | 10.3 | 11.1 | 95.0 | 103.0 | 100.9 |
| 10.0 | 13.0 | 20.0 | 9.2 | 12.99 | 18.4 | 92.0 | 99.9 | 92.0 |
| 4.0 | 1.0 | 15.0 | 3.8 | 0.99 | 15.3 | 95.0 | 99.0 | 102.0 |
| 5.0 | 7.0 | 11.0 | 5.1 | 6.5 | 11.4 | 102.0 | 92.9 | 103.6 |
| 19.0 | 13.0 | 4.0 | 19.1 | 13.8 | 3.9 | 100.5 | 106.2 | 97.5 |
| Mean recovery | 98.4 | 100.1 | 100.3 | |||||
| R.S.E. (%) single | 3.22 | 3.08 | 4.59 | |||||
| R.S.E. (%) total | 3.81 | |||||||
Assayed results of simultaneous determination of PCT, PHEN and CHL in Adult cold tablets by the proposed methods.
| PCT | PHEN | CHL | |||||||
|---|---|---|---|---|---|---|---|---|---|
| PCR | PLS1 | PLS2 | PCR | PLS1 | PLS2 | PCR | PLS1 | PLS2 | |
| Sample 1 (mg) | 324.0 | 323.2 | 323.9 | 5.01 | 5.03 | 5.05 | 1.99 | 2.02 | 1.99 |
| Sample 2 (mg) | 323.5 | 325.6 | 324.0 | 5.02 | 5.01 | 5.04 | 1.98 | 2.01 | 2.01 |
| Sample 3 (mg) | 325.5 | 324.8 | 326.3 | 4.99 | 5.02 | 4.99 | 1.96 | 1.99 | 2.01 |
| Sample 4 (mg) | 323.7 | 326.1 | 326.1 | 4.98 | 4.98 | 4.97 | 2.01 | 1.97 | 1.97 |
| Sample 5 (mg) | 325.5 | 325.6 | 324.2 | 4.98 | 4.97 | 5.08 | 2.01 | 1.98 | 1.99 |
| Amount on the label (mg) | 325.0 | 325.0 | 325.0 | 5.00 | 5.00 | 5.00 | 2.00 | 2.00 | 2.00 |
| Mean% recovery | 99.8 | 100.0 | 99.9 | 99.9 | 100.0 | 100.5 | 99.5 | 99.7 | 99.7 |
| SD% recovery | 0.30 | 0.35 | 0.37 | 0.35 | 0.52 | 0.90 | 1.06 | 1.04 | 0.84 |
Figure 3Absorbance spectra of: (I) Mixture of PCT, PHEN and CHL; (II) Commercial formulation (Adult cold) in methanol: 0.1 M HCl (3:1).
Composition of synthetic samples, their predictions by PLS1 model and statistical parameters for the system.
| Synthetic (µgml-1) | Prediction (µgml-1) | Recovery (%) | ||||||
|---|---|---|---|---|---|---|---|---|
| PCT | PHEN | CHL | PCT | PHEN | CHL | PCT | PHEN | CHL |
| 18.0 | 10.0 | 16.0 | 18.1 | 10.1 | 15.7 | 100.6 | 101.0 | 98.1 |
| 17.0 | 1.0 | 11.0 | 17.9 | 1.0 | 11.2 | 105.3 | 100.0 | 101.8 |
| 9.0 | 20.0 | 16.0 | 8.6 | 19.8 | 16.3 | 95.6 | 99.0 | 101.9 |
| 9.0 | 13.0 | 6.0 | 8.8 | 13.0 | 5.6 | 97.8 | 100.0 | 93.3 |
| 16.0 | 4.0 | 19.0 | 15.9 | 4.1 | 17.9 | 99.4 | 102.5 | 94.2 |
| 2.0 | 10.0 | 11.0 | 2.3 | 9.8 | 10.9 | 115.0 | 98.0 | 99.1 |
| 10.0 | 13.0 | 20.0 | 9.8 | 13.2 | 19.1 | 98.0 | 101.5 | 95.5 |
| 4.0 | 1.0 | 15.0 | 4.1 | 0.99 | 15.6 | 102.5 | 99.0 | 104.0 |
| 5.0 | 7.0 | 11.0 | 4.9 | 6.8 | 11.2 | 98.0 | 97.1 | 101.8 |
| 19.0 | 13.0 | 4.0 | 18.9 | 13.5 | 3.9 | 99.5 | 103.8 | 97.5 |
| Mean recovery | 101.2 | 100.2 | 98.7 | |||||
| R.S.E. (%) single | 2.78 | 1.91 | 3.84 | |||||
| R.S.E. (%) total | 3.10 | |||||||